Juan Carlos Ivancevich
Overview
Explore the profile of Juan Carlos Ivancevich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
523
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sousa-Pinto B, Costa E, Vieira R, Klimek L, Czarlewski W, Pfaar O, et al.
Clin Exp Allergy
. 2025 Feb;
55(3):226-238.
PMID: 39956639
Background: Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK-air mHealth app to assess adherence to oral antihistamines (OAH), intra-nasal corticosteroids (INCS) or...
2.
Bousquet J, Sousa-Pinto B, Anto J, Bedbrook A, Czarlewski W, Ansotegui I, et al.
Clin Transl Allergy
. 2024 Sep;
14(9):e12390.
PMID: 39313483
Patient-reported outcome measures (PROMs) are used to assess a patient's health status at a particular point in time. They are essential in the development of person-centred care. This paper reviews...
3.
Bousquet J, Schunemann H, Sousa-Pinto B, Zuberbier T, Togias A, Samolinski B, et al.
J Allergy Clin Immunol Pract
. 2024 Jul;
12(10):2648-2668.e2.
PMID: 38971567
The traditional healthcare model is focused on diseases (medicine and natural science) and does not acknowledge patients' resources and abilities to be experts in their own lives based on their...
4.
Cherrez-Ojeda I, Bousquet J, Gimenez-Arnau A, Godse K, Krasowska D, Bartosinska J, et al.
J Allergy Clin Immunol Pract
. 2024 May;
12(8):2211-2215.e1.
PMID: 38734372
No abstract available.
5.
Cherrez-Ojeda I, Bousquet J, Gimenez-Arnau A, Godse K, Krasowska D, Bartosinska J, et al.
J Allergy Clin Immunol Pract
. 2024 Apr;
12(6):1575-1583.e1.
PMID: 38604531
Background: Patient-reported outcome measures (PROMs) are validated and standardized tools that complement physician evaluations and guide treatment decisions. They are crucial for monitoring atopic dermatitis (AD) and chronic urticaria (CU)...
6.
Sousa-Pinto B, Louis G, Rodrigues J, Giuliano A, Baiardini I, Braido F, et al.
J Allergy Clin Immunol Pract
. 2023 Aug;
11(12):3742-3751.e9.
PMID: 37572753
Background: EQ-5D-5L (EuroQOL, 5 Domains, 5 Levels) is a widely used health-related quality-of-life instrument, comprising 5 domains. However, it is not known how each domain is impacted by rhinitis or...
7.
Tiotiu A, Bikov A, Gonzalez-Barcala F, Novakova S, Novakova P, Chong-Neto H, et al.
Expert Rev Respir Med
. 2023 Jun;
17(6):507-516.
PMID: 37313643
Background: Currently, there are no universally accepted criteria to measure the response to biologics available as treatment for severe asthma. This survey aims to establish consensus criteria to use for...
8.
Aeroallergen immunotherapy associated with reduced risk of severe COVID-19 in 1095 allergic patients
Larenas-Linnemann D, Morfin-Maciel B, Bedolla-Barajas M, Lopez-Bago A, Navarrete Rodriguez E, Mogica-Martinez M, et al.
World Allergy Organ J
. 2023 May;
16(5):100779.
PMID: 37251811
Introduction: Allergen immunotherapy (AIT) brings along changes in the immune system, restoring dendritic cell function, reducing T2 inflammation and augmenting the regulatory cell activation. Coronavirus disease (COVID-19), caused by severe...
9.
Bousquet J, Shamji M, Anto J, Schunemann H, Canonica G, Jutel M, et al.
Allergy
. 2023 Apr;
78(7):1758-1776.
PMID: 37042071
Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely...
10.
Bousquet J, Anto J, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahtela T, et al.
Clin Transl Allergy
. 2023 Jan;
13(1):e12215.
PMID: 36705508
MASK-air , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to...